A phase I and pharmacokinetic study of intraperitoneal carboplatin and etoposide.

BACKGROUND: We attempted to determine the maximum tolerated dose and toxicity of etoposide (VP-16) when administered in combination with carboplatin (CBDCA) (300 mg m-2) and administered via the intraperitoneal (IP) route. METHODS AND MATERIALS: A total of 26 patients were treated on this trial. CBD...

詳細記述

保存先:
書誌詳細
主要な著者: McClay, E. F., Goel, R., Andrews, P., Gorelick, S., Kirmani, S., Kim, S., Braly, P., Plaxe, S., Hoff, S., Alcaraz, J.
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group 1993
主題:
Research Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC1968622/
https://ncbi.nlm.nih.gov/pubmed/8398708
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料